MedTrace Logo

NDPH Biomarker Study in Children and Adolescents

NCT06018025 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2025-12-01

No results posted yet for this study

Summary

This study will recruit pediatric patients with NDPH (New Daily Persistent Headache), characterize their headache in a standard manner, and treat the NDPH with standard medications used for treatment of headaches in this population. Response to treatment with CGRP blocking Ab medications will be evaluated. Biomarkers related to headache disorders will be measured before and after treatment.

Conditions

  • New Persistent Daily Headache

Interventions

DRUG

CGRP antibody

treatment with CGRP antibody for 4 months

Sponsors & Collaborators

  • International Headache Society

    collaborator UNKNOWN

  • Duke University

    lead OTHER

Principal Investigators

  • Klaus Werner, MD · Duke University

Eligibility

Min Age
10 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-15
Primary Completion
2025-05-29
Completion
2025-05-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06018025 on ClinicalTrials.gov